ArticleBiomedica : revista del Instituto Nacional de Salud2026
Effect of ivermectin on Toxocara canis larvae in vitro and in vivo at different migratory stages
Article in Biomedica : revista del Instituto Nacional de Salud, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionIvermectin has shown potent activity against various nematodes.
objectiveEvaluation of the efficacy of ivermectin against Toxocara canis larvae. MATERIALS AND
methodsIn vitro assessment was conducted using larval migration inhibition test and scanning electron microscopy (SEM). In vivo, ivermectin was administered orally to mice at a single 0.2 mg/kg dose at 2 (group I), 7 (group II), or 15 days (group III) post-infection. Efficacy was evaluated through brain larval counts and histopathological examination of liver and brain.
resultsIn vitro, ivermectin at concentrations of 10 μg/ml and 100 μg/ml inhibited larval migration by 8.5% and 87%, respectively. SEM showed cuticular damage after 24 and 48 hours with 100 μg/ml ivermectin. In vivo, brain larval counts significantly decreased in groups I and II (22.67 ± 5.41 and 37.17 ± 5.98), with no significant reduction in group III (130.5 ± 9.01). Histopathology of the liver at four weeks post-infection in groups I and II revealed numerous granulomas with degenerated larvae. The brain showed a marked reduction in larval presence and inflammation in groups I and II, while group III findings were similar to those of the control group.
conclusionIvermectin is effective against T. canis larvae during early migratory stages but shows limited efficacy against late-stage larvae.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.